J&J subsidiaries ink $65M deal to resolve Tracleer antitrust case
Seeking Alpha
Johnson & Johnson subsidiaries will pay $65M to settle an antitrust lawsuit concerning their lung disorder therapy, Tracleer.Summary
Johnson & Johnson (JNJ) subsidiaries, Actelion Pharmaceuticals and Janssen Research & Development, have reached a $65 million settlement to resolve a proposed antitrust class action lawsuit. The suit revolved around J&J’s lung disorder therapy, Tracleer. This agreement brings an end to the legal challenge concerning potential antitrust violations related to the drug.
(Source：Seeking Alpha)